DDInter1252 DDInter1376
Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency. However, mycophenolic acid treatment is more expensive and requires therapeutic drug monitoring to optimize efficacy and minimize toxicity.[A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Mycophenolic acid {u} (Compound) resembles {v} (Compound) Mycophenolate mofetil
Mycophenolic acid {u} (Compound) treats {v} (Disease) systemic scleroderma
Mycophenolic acid {u} (Compound) binds {v} (Gene) IMPDH1
Mycophenolic acid {u} (Compound) upregulates {v} (Gene) UBE2L6
Mycophenolic acid {u} (Compound) downregulates {v} (Gene) SETD5
Mycophenolic acid {u} (Compound) causes {v} (Side Effect) Nervous system disorder
Mycophenolic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ethotoin
Mycophenolic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Mycophenolic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tigecycline
Mycophenolic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Candida albicans
Mycophenolic acid (Compound) resembles Mycophenolate mofetil (Compound)
Mycophenolic acid (Compound) treats systemic scleroderma (Disease)
Mycophenolic acid (Compound) binds IMPDH1 (Gene)
Mycophenolic acid (Compound) upregulates UBE2L6 (Gene)
Mycophenolic acid (Compound) downregulates SETD5 (Gene)
Mycophenolic acid (Compound) causes Nervous system disorder (Side Effect)
Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ethotoin
Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Tigecycline
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans